Braveheart Bio (BRVE) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases.

• Lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor for obstructive and non-obstructive HCM.

• BHB-1893 in-licensed from Jiangsu Hengrui Pharmaceuticals; all clinical trials to date conducted by Hengrui, primarily in China.

• Plans to initiate global Phase 3 trials in oHCM (2H 2026) and nHCM (1H 2027), with additional pipeline expansion possible.

Financial performance and metrics

• Net loss of $66.1 million for the year ended December 31, 2025; $14.3 million net loss for the three months ended March 31, 2026.

• Accumulated deficit of $80.3 million as of March 31, 2026.

• Cash and cash equivalents of $80.6 million as of March 31, 2026; $60 million additional Series A preferred stock proceeds in April 2026.

• No revenue generated to date; all funding from equity issuances.

Use of proceeds and capital allocation

• Estimated net proceeds of $274.5 million from IPO (or $316.4 million if underwriters' option exercised), assuming $16.00 per share.

• Proceeds to fund Phase 3 trials for BHB-1893 in oHCM and nHCM, R&D personnel and overhead, and general corporate purposes.

• Sufficient to fund operations into 2029 based on current plans.